Frontlight ResearchEarly access
WithdrawnNo phase
SAINT for Treatment of Preoperative Depression to Reduce Opioid Use Following Arthroplasty
Key facts
- Who runs it
- Stanford University
- Where
- Stanford, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- Jun 2024
- Expected to end
- Nov 2026
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Active TBS-DLPFC
- Sham TBS-DLPFC
- Open label TBS-DLPFC
- Record updated
- 14 December 2022
- Why it stopped
- Logistical constraints
Who can take part
- Age
- 22 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (39)Hide the full registry criteria
Who can take part
- Male or female, 22 to 80 years of age
- Able to provide informed consent
- Diagnosed with Major Depressive Disorder (MDD) and currently experiencing a Major Depressive Episode (MDE)
- Participants may currently be on a stable and adequate dose of SSRI antidepressant therapy. Participants may choose to not be on antidepressant therapy for the study duration, or to be switched from other classes to a medication from the SSRI class
- Participants may also have a history of intolerance to at least 2 antidepressant medications. These patients with the intolerance history will not be required to be currently taking an antidepressant medication
- Participants must qualify as "Moderately Treatment Refractory" or "High Treatment Refractory" using the Maudsley staging method
- Meet the threshold on the total HAMD17 score of >/=20 at both screening and baseline visits (Day -5/-14 and Day 0)
- Meet the threshold on the total MADRS score of >/=20 at both screening and baseline visits (Day -5/-14 and Day 0)
- Meet the threshold on the total BDI-II score of >/=20 at both screening and baseline visits (Day -5/-14 and Day 0)
- In good general health, as ascertained by medical history
- If female, a status of non-childbearing potential or use of an acceptable form of birth control. The form of birth control will be documented at screening and baseline
- Concurrent hypnotic therapy (e.g., with zolpidem, zaleplon, melatonin, or trazodone) will be allowed if the therapy has been stable for at least 4 weeks prior to screening and if it is expected to remain stable
Who cannot take part
- Current diagnosis of a Substance Use Disorder (Abuse or Dependence, as defined by DSM-IV-TR), with the exception of nicotine dependence, at screening or within six months prior to screening
- History of schizophrenia or schizoaffective disorders, or any history of psychotic symptoms in the current or previous depressive episodes
- Any Axis I or Axis II Disorder, which at screening is clinically predominant to their MDD or has been predominant to their MDD at any time within six months prior to screening
- Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation
- Current diagnosis of Axis I disorders other than Dysthymic Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia, or Specific Phobia (unless one of these is comorbid and clinically unstable, and/or the focus of the participant's treatment for the past six months or more)
- Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation
- History of positive screening urine test for drugs of abuse at screening: cocaine, amphetamines, barbiturates, opiates
- History of epilepsy
- History of rTMS exposure
- History of any implanted device or psychosurgery for depression
- History of ECT intolerance
- History of shrapnel or metal in the head or skull
- History of cardiovascular disease or cardiac event
- History of OCD
- History of autism spectrum disorder
- History of intractable migraine
- History of independent sleep disorder
- Female of childbearing potential who is not willing to use one of the specified forms of birth control during the study
- Female that is pregnant or breastfeeding
- Female with a positive pregnancy test at participation
- Total HAMD17 score of < 20 at the screen or baseline visits
- Total MADRS score of < 20 at the screen or baseline visits
- Total BDI-II score of < 20 at the screen or baseline visits
- Considered at significant risk for suicide during the course of the study
- Has a clinically significant abnormality on the screening examination that might affect safety, study participation, or confound interpretation of study results
- Current (or chronic) use of opiates
- "Low Treatment Refractory" using the Maudsley staging method
Where in United States
- Department of Psychiatry and Behavioral Sciences, Stanford School of MedicineStanford, United States
About the trial
What the trial wants to find out
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression. In a double-blind fashion, half the participants will receive accelerated theta-burst stimulation while half will receive sham treatment.
The 2 groups in the trial
- Active TBS-DLPFCTreatment being tested
The active group will receive theta-burst TMS stimulation.
- Sham TBS-DLPFCSham treatment, for comparison
The sham group will receive sham theta-burst TMS stimulation. Participants will have the option of open label TBS-DLPFC treatment following study completion.
Treatment: Sham TBS-DLPFC and Open label TBS-DLPFC
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Accelerated Intermittent Theta-burst Stimulation for Treatment of Preoperative Depression to Reduce Conversion of Acute to Chronic Opioid Use Following Arthroplasty
- Record updated
- 14 December 2022